Ziglim Plus 1 Tablet SR is a combination oral antidiabetic medication formulated to improve glycemic control in patients with type 2 diabetes mellitus. Each sustained-release tablet contains Glimepiride 1 mg, Metformin 500 mg, and Pioglitazone 15 mg, which act synergistically through complementary mechanisms to achieve optimal blood glucose regulation. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to enhance insulin secretion. Metformin, a biguanide, primarily reduces hepatic glucose production and improves peripheral insulin sensitivity, while Pioglitazone, a thiazolidinedione, enhances insulin sensitivity in adipose tissue, muscle, and the liver by activating peroxisome proliferator-activated receptor gamma (PPAR-γ). This triple combination is indicated for patients inadequately controlled on monotherapy or dual therapy, providing improved efficacy in lowering fasting and postprandial blood glucose levels. Ziglim Plus 1 Tablet SR should be administered once daily with meals to minimize gastrointestinal side effects and ensure sustained drug release. It is essential to monitor renal and hepatic function periodically during therapy. Contraindications include type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and hypersensitivity to any component. Common adverse effects may include hypoglycemia, gastrointestinal disturbances, weight gain, and edema. Patient adherence to lifestyle modifications remains crucial for optimal therapeutic outcomes.